The Latest Psychedelics Articles from Streetwise Reports

Former NFL Safety Director Joins Neurotherapy Firm Advisory Board

  ()
Treating traumatic brain injury with alternative pharmaceuticals is delicate work. Now one Canadian firm has enlisted the help of former National Football League Neurological Player Care Safety Director Dr. David Brody.
Tags:  PsychedelicsBiotechnology / Pharmaceuticals

Addiction Therapy Company Secures Major UK Endorsement

  ()
Pharmaceutical powerhouse Awakn has been awarded Innovative Licensing and Access Pathway (ILAP) access to UK markets. This classification, equivalent to FDA Breakthrough Therapy designation in the U.S., allows the company to expedite development growth in the region.
Tags:  PsychedelicsHealthcare Services

Biotech's Novel Thin Formulation Improves Veteran-Aiding Treatment

  ()
This morning Awakn Life Sciences announced further details regarding its August 2022 announcement that it had "signed a twelve-month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of administration for ketamine." Read to learn more about this announcement, the benefits of this treatment, and what analysts and experts are saying about the company.
Tags:  PsychedelicsBiotechnology / Pharmaceuticals

Exploring Why The Economist Named this Biotech 'One To watch' in 2023

  ()
As more researchers delve into the medicinal potentials of once-verboten compounds, forward-thinking companies like Awakn Life Sciences Corp. are leading the charge to map their most useful aspects and open access for people who need help now. Read more to learn what catalysts Awakn has in store and why The Economist touched on this treatment as one of their top stories of 2023.
Tags:  PsychedelicsHealthcare ServicesBiotechnology / Pharmaceuticals

Biotech at Good Entry Point for Investors, Analyst Says

Research Report
  ()
The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market is valuing it at, noted a Stifel report.
Tags:  Psychedelics

Why One Fund Owns 13% of This Small-Cap Pharma

  ()
Clinical-stage Algernon Pharmaceuticals' multiple pipelines include testing a psychedelic for the treatment of stroke, and testing other drugs for idiopathic pulmonary fibrosis and chronic kidney disease.
Tags:  PsychedelicsBiotechnology / Pharmaceuticals

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

  ()
This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon.
Tags:  PsychedelicsBiotechnology / Pharmaceuticals

Potential ROI With German Biopharma Co. Notable

Research Report
  ()
This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report.
Tags:  PsychedelicsBiotechnology / Pharmaceuticals

Biopharma Target Price 10 Times Current

Research Report
  ()
Read to learn why ROTH Capital Partners gave Atai Life Sciences NV a Buy rating and a target price 10 times its current.
Tags:  Psychedelics

Opportunity for Investors Found in Psychedelics Space

Research Report
  ()
Treatment of alcohol use disorder with psychedelics plus therapy is effective, according to existing data, and the potential global market is large, noted an H.C. Wainwright & Co. report.
Tags:  Psychedelics

Showing Results: 1 to 10 of 10